Australia markets closed

ChemoCentryx, Inc. (CCXI)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
25.34-0.27 (-1.05%)
At close: 04:00PM EST
25.00 -0.34 (-1.34%)
After hours: 05:48PM EST

ChemoCentryx, Inc.

835 Industrial Avenue
Suite 600
San Carlos, CA 94070
United States
650 210 2900

Full-time employees133

Key executives

NameTitlePayExercisedYear born
Dr. Thomas J. Schall Ph.D.Founder, Pres, CEO & Chairman1.13M23.5M1959
Ms. Susan M. KanayaExec. VP, Chief Financial & Admin. Officer, Sec. and Director757.77k14.74M1963
Dr. Rita I. Jain M.D.Exec. VP, Chief Medical Officer & Exec. Employee Director76kN/A1963
Dr. Markus J. Cappel Ph.D.Sr. VP, Chief Bus. Officer & Treasurer607.52k18.44M1961
Mr. Tausif ButtExec. VP & COON/AN/A1966
Ms. Kari E. LeetchSr. VP of HRN/AN/AN/A
Ms. Dalia R. RayesSr. VP & Head of CommercialN/AN/AN/A
Dr. Sangita Ghosh Ph.D.Sr. VP of Technical OperationsN/AN/AN/A
Amounts are as of 31 December 2020, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It develops Avacopan, an orally administered selective complement 5a receptor inhibitor for the treatment of anti-neutrophil cytoplasmic autoantibody-associated vasculitis; and completed Phase II clinical trial for the treatment of patients with severe hidradenitis suppurativa, as well as patients with complement 3 glomerulopathy. The company is also developing CCX559, an orally-administered inhibitor for programmed death protein 1/programmed death-ligand 1 for the treatment of various cancers; and CCX507, an orally-administered inhibitor of the chemokine receptor CC9, which has completed Phase I clinical trial or the treatment of inflammatory bowel disease. In addition, it develops CCX587 for the treatment of TH17 driven diseases. ChemoCentryx, Inc. was incorporated in 1996 and is headquartered in San Carlos, California.

Corporate governance

ChemoCentryx, Inc.’s ISS governance QualityScore as of 26 September 2021 is 4. The pillar scores are Audit: 7; Board: 4; Shareholder rights: 5; Compensation: 5.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.